Drug Information
Drug General Information | Top | |||
---|---|---|---|---|
Drug ID |
D4Z5CU
|
|||
Drug Name |
M710
|
|||
Synonyms |
637-01-4; N,N,N',N'-Tetramethyl-p-phenylenediamine dihydrochloride; N1,N1,N4,N4-tetramethylbenzene-1,4-diamine dihydrochloride; N,N,N',N'-Tetramethyl-1,4-phenylenediamine Dihydrochloride; UNII-66W8HKA51X; MFCD00012482; 66W8HKA51X; tetramethyl-p-phenylenediamine dihydrochloride; 1,4-Benzenediamine, N,N,N',N'-tetramethyl-, dihydrochloride; NSC36730; 1,4-Benzenediamine, N1,N1,N4,N4-tetramethyl-, hydrochloride (1:2); 1-N,1-N,4-N,4-N-tetramethylbenzene-1,4-diamine;dihydrochloride; Wursters Reagent; N,N,N',N'-Tetramethyl-p-phenylenediamine dihydrochloride, 99%; EINECS 211-274-8; NSC 36730; TMPPD; ACMC-1B8O0; SCHEMBL379125; DTXSID2060915; N,N,N',N'-Tetramethyl-para-phenylenediamine dihydrochloride; ANW-34710; AKOS005254702; MCULE-3840175847; VZ32824; AS-14819; SY061584; 3-(4-Bromo-1H-pyrazol-1-yl)propanoicacid; DB-054526; FT-0629355; ST50308398; Tetramethyl-p-phenylene diamine hydrochloride; 1,4-Bis(dimethylamino)benzene dihydrochloride; X-4255; N,N,N',N'-Tetramethyl-p-phenylenediamine 2HCl; N,N,N',N'-Tetramethyl-p-phenylenediamine DiHCl; W-104885; Q27264036; [4-(dimethylamino)phenyl]dimethylamine, chloride, chloride; N,N,N\\',N\\'-Tetramethyl-p-phenylenediamine dihydrochloride; N1,N1,N4,N4-Tetramethyl-1,4-benzenediamine Dihydrochloride; p-Phenylenediamine, N,N,N',N'-tetramethyl-, dihydrochloride (8CI); N,N,N',N'-Tetramethyl-p-phenylenediamine dihydrochloride, >=95%, powder; N,N,N',N'-Tetramethyl-p-phenylenediamine dihydrochloride, >=97.0% (AT)
Click to Show/Hide
|
|||
Drug Type |
Small molecular drug
|
|||
Indication | Diabetic macular edema [ICD-11: 9B71.02] | Phase 3 | [1] | |
Company |
Momenta Pharmaceuticals; Mylan
|
|||
Structure |
Download2D MOL
|
|||
Formula |
C10H18Cl2N2
|
|||
Canonical SMILES |
CN(C)C1=CC=C(C=C1)N(C)C.Cl.Cl
|
|||
InChI |
1S/C10H16N2.2ClH/c1-11(2)9-5-7-10(8-6-9)12(3)4;;/h5-8H,1-4H3;2*1H
|
|||
InChIKey |
FBHKTSXMTASXFJ-UHFFFAOYSA-N
|
|||
CAS Number |
CAS 637-01-4
|
|||
PubChem Compound ID |
Target and Pathway | Top | |||
---|---|---|---|---|
Target(s) | Vascular endothelial growth factor (VEGF) | Target Info | Inhibitor | [1] |
References | Top | |||
---|---|---|---|---|
REF 1 | ClinicalTrials.gov (NCT03610646) Comparative Study to Evaluate the Efficacy and Safety of MYL-1701P and Eylea in Subjects With Diabetic Macular Edema. U.S. National Institutes of Health. |
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.